Cellebrite DI (NASDAQ:CLBT – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $0.10 per share and revenue of $107.26 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Cellebrite DI Price Performance
Shares of CLBT opened at $25.46 on Tuesday. The business’s 50 day simple moving average is $22.31 and its 200-day simple moving average is $18.89. Cellebrite DI has a 1 year low of $8.91 and a 1 year high of $26.30. The stock has a market capitalization of $5.24 billion, a price-to-earnings ratio of -16.43, a price-to-earnings-growth ratio of 3.72 and a beta of 1.47.
Wall Street Analyst Weigh In
CLBT has been the topic of a number of research reports. Craig Hallum raised their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC upped their price objective on shares of Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. boosted their price objective on Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $21.57.
Cellebrite DI Company Profile
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Read More
- Five stocks we like better than Cellebrite DI
- What is a support level?
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Consumer Staples Stocks, Explained
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- What Are Dividend Champions? How to Invest in the Champions
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.